Social Media Ideas for Joe Jimenez

PhRMA names next CEO; Pierre Fabre takes third swing at Ebvallo approval

A former congressman will take over for prominent lobbyist Steve Ubl. Elsewhere, recent buyout deals paid dividends for Mirum and AbbVie.

The GLP-1 Era Has a Name. It's David Ricks.

Study 11 of the 5W Reputation Index looks at how AI engines describe 18 pharma CEOs, and how the GLP-1 shift rewrites all of those profiles at once.

<![CDATA[Pharmaceutical Executive Daily: Fabrice Chouraqui Steps Down as CEO of Pharming]]>

<![CDATA[Pharming CEO Fabrice Chouraqui Steps Down Amid Strategic Disagreement with Board]]>

<![CDATA[Bausch + Lomb Appoints Thomas Appio as Interim CEO ]]>

<![CDATA[Pharmaceutical Executive Daily: David Samra Calls For Novartis Board Shake-Up]]>

<![CDATA[CSL Names Deborah Waterhouse as CEO and Manager Director ]]>

Moderna Adds Chief Operating Officer Role as Company Expands into Oncology

Juan Andres to Return to Moderna as Chief Operating OfficerJerh Collins to Retire Following Four Years of Leadership at Moderna

<![CDATA[Artisan Partners’ Director Calls for Novartis Board Shake-Up ]]>

<![CDATA[ Eli Lilly to Acquire Merida Biosciences for $2.8 Billion ]]>

Laboratoires Pierre Fabre appoints Zombré CEO of U.S. Dermocosmetics operations in Secaucus

Laboratoires Pierre Fabre, the world’s second-largest dermo-cosmetics company and one of Europe’s leading pharmaceutical groups, announced Aug. 25 the appointment of Nicolas Zombré...

<![CDATA[Roundup: Shionogi Inc. Acquires IntraBio, Gate Bioscience extends Collaboration with Eli Lilly, Alector Ente...

Jim Beam maker chooses next chief supply chain officer

Manuel Cabañas has been with Suntory Global Spirits since 2000 and will now oversee global manufacturing, distribution, quality, sourcing and operations.

<![CDATA[Trump Administration Adds Nine Drugmakers to Most-Favored-Nation Program: Report ]]>

<![CDATA[Life Sciences Liabilities Change Character as Companies Grow: Q&A with Jennifer Ampulski]]>

<![CDATA[Roundup: FDA Approves Lilly’s Olumiant, AbbVie’s Juvmo, Mirum & Incyte’s Atebrioz ]]>

<![CDATA[A Leadership Call to Action for Biotech]]>

<![CDATA[How QMM Can Help the C-Suite See a $100 Million Problem Early]]>

Andy Plump, architect of Takeda’s R&D overhaul, to retire next year

Plump joined Takeda during a turbulent period, pushed the company to work more closely with young biotechs and will leave it with what CEO Julie Kim called a “lasting foundation.”

Iambic CEO on taking an AI drug company public

Fresh off a $150 million IPO, Tom Miller spoke to BioPharma Dive about the roadshow process and how he sees AI’s role in drug development evolving.

Oncology WW VP

Oncology WW VP Anonymous (not verified) Tue, 09/15/2026 - 18:53 field_thread_url https://cafepharma.com/boards/threads/oncology-ww-vp.715506/...

<![CDATA[Pharmaceutical Executive Daily: FDA Approves Tecentriq]]>

Jim Beam maker chooses next chief supply chain officer

Manuel Cabañas has been with Suntory Global Spirits since 2000 and will now oversee manufacturing, distribution, quality, sourcing and operations across the company’s global networ...

<![CDATA[AstraZeneca Taps insitro AI for MASH in Deal Worth Up to $1.5 Billion]]>